Sunesis Pharmaceuticals (SNSS) Receiving Somewhat Favorable Press Coverage, Report Shows

News coverage about Sunesis Pharmaceuticals (NASDAQ:SNSS) has trended somewhat positive this week, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sunesis Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.6648911970537 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) opened at $3.76 on Tuesday. The company has a debt-to-equity ratio of -0.34, a quick ratio of 1.84 and a current ratio of 1.84. Sunesis Pharmaceuticals has a 12-month low of $1.82 and a 12-month high of $4.45. The company has a market capitalization of $128.77, a P/E ratio of -2.15 and a beta of 1.53.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). During the same period in the previous year, the firm posted ($0.62) earnings per share. analysts predict that Sunesis Pharmaceuticals will post -1.58 EPS for the current fiscal year.

Several analysts recently commented on the company. Cantor Fitzgerald reiterated a “hold” rating and set a $3.00 price target on shares of Sunesis Pharmaceuticals in a research report on Wednesday, September 27th. Cowen reiterated a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Thursday, November 2nd. Zacks Investment Research cut Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Oppenheimer assumed coverage on Sunesis Pharmaceuticals in a research report on Tuesday, November 21st. They set an “outperform” rating and a $7.00 price target for the company. Finally, UBS Group assumed coverage on Sunesis Pharmaceuticals in a research report on Monday, November 20th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $3.75.

In related news, major shareholder Mpm Oncology Impact Management bought 25,300 shares of the company’s stock in a transaction on Thursday, November 2nd. The stock was bought at an average cost of $2.59 per share, for a total transaction of $65,527.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Dayton Misfeldt bought 400,000 shares of the company’s stock in a transaction on Friday, October 27th. The stock was bought at an average price of $2.00 per share, with a total value of $800,000.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 506,800 shares of company stock valued at $1,091,282. 10.21% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2018/01/09/sunesis-pharmaceuticals-snss-receiving-somewhat-favorable-press-coverage-report-shows.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Insider Buying and Selling by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit